Ultrasound technology developer Misonix of Farmingdale, NY, said that researchers attending last month's American Urological Association (AUA) meeting in Anaheim, CA, reported positive results with the firm's prostate hemiablation therapy device, SB500.
In clinical experience reported at the meeting by Dr. T. Uchida from Tokai University in Tokyo, the SB500 high-intensity focused ultrasound (HIFU) ablation therapy using the latest software (version 4.0 with enhanced 3D imaging capabilities) reduced treatment times by 48%, with a procedural success rate of 94%, a 50% improvement compared to results with the previous software version, according to Misonix.
At a user group meeting for the device, Dr. Mark Emberton from the Royal College of Surgeons in the U.K., reported postprocedural continence and potency rates of 100%, respectively, with successful ablation of cancerous tissues in all patients using the device, Misonix said. In the past six years, the device has treated more than 6,000 treatments in more than 100 clinics.
By AuntMinnie.com staff writers
June 6, 2007
Related Reading
Misonix reports HIFU hemiablation success, March 29, 2007
Misonix establishes HIFU clinical registry, March 27, 2007
Misonix reports HIFU kidney trial success, March 22, 2007
Misonix, Partnermed sign Scandinavian HIFU deal, March 6, 2007
Constantine leaves Misonix, January 9, 2007
Copyright © 2007 AuntMinnie.com
